| [1] |
Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(1): 17-48. DOI: 10.3322/caac.21763.
|
| [2] |
Masci D, Naro C, Puxeddu M, et al. Recent advances in drug discovery for triple-negative breast cancer treatment[J]. Molecules, 2023, 28(22): 7513. DOI: 10.3390/molecules28227513.
|
| [3] |
谢露露, 丁江华. 免疫治疗在晚期三阴性乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(11): 672-676. DOI: 10.3760/cma.j.cn371439-20230722-00127.
|
| [4] |
Adrada BE, Moseley TW, Kapoor MM, et al. Triple-negative breast cancer: histopathologic features, genomics, and treatment[J]. Radiographics, 2023, 43(10): e230034. DOI: 10.1148/rg.230034.
|
| [5] |
Hadebe B, Harry L, Ebrahim T, et al. The role of PET/CT in breast cancer[J]. Diagnostics, 2023, 13(4): 597. DOI: 10.3390/diagnostics 13040597.
|
| [6] |
McDonald ES, Clark AS, Tchou J, et al. Clinical diagnosis and management of breast cancer[J]. J Nucl Med, 2016, 57 Suppl 1: 9S-16 S. DOI: 10.2967/jnumed.115.157834.
|
| [7] |
Andryszak N, Świniuch D, Wójcik E, et al. Head-to-head comparison of [18F]PSMA-1007 and [18F]FDG PET/CT in patients with triple-negative breast cancer[J]. Cancers (Basel), 2024, 16(3): 667. DOI: 10.3390/cancers16030667.
|
| [8] |
Romeo V, Kapetas P, Clauser P, et al. A simultaneous multiparametric 18F-FDG PET/MRI radiomics model for the diagnosis of triple negative breast cancer[J]. Cancers (Basel), 2022, 14(16): 3944. DOI: 10.3390/cancers14163944.
|
| [9] |
Arslan E, Çermik TF, Trabulus FDC, et al. Role of 18F-FDG PET/CT in evaluating molecular subtypes and clinicopathological features of primary breast cancer[J]. Nucl Med Commun, 2018, 39(7): 680-690. DOI: 10.1097/MNM.0000000000000856.
pmid: 29893750
|
| [10] |
Seban RD, Arnaud E, Loirat D, et al. [18F]FDG PET/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab[J]. Eur J Nucl Med Mol Imaging, 2023, 50(13): 4024-4035. DOI: 10.1007/s00259-023-06394-y.
|
| [11] |
Gao Y, Yin L, Ma L, et al. Comparative analysis of metabolic cha-racteristics and prognostic stratification of HER2-low and HER2-zero breast cancer using 18F-FDG PET/CT imaging[J]. Cancer Imaging, 2024, 24(1): 166. DOI: 10.1186/s40644-024-00812-6.
|
| [12] |
Roy M, Fowler AM, Ulaner GA, et al. Molecular classification of breast cancer[J]. PET Clin, 2023, 18(4): 441-458. DOI: 10.1016/j.cpet.2023.04.002.
pmid: 37268505
|
| [13] |
康佳, 吴桐, 张蕾, 等. 不同分子分型乳腺癌的多模态超声特征和临床病理对照研究[J]. 中华超声影像学杂志, 2020, 29(4): 330-336. DOI: 10.3760/cma.j.cn131148-20190926-00591.
|
| [14] |
Costantini M, Belli P, Bufi E, et al. Association between sonographic appearances of breast cancers and their histopathologic features and biomarkers[J]. J Clin Ultrasound, 2016, 44(1): 26-33. DOI: 10.1002/jcu.22312.
pmid: 26402438
|
| [15] |
Sannomiya N, Hattori Y, Ueda N, et al. Correlation between ultrasound findings of tumor margin and clinicopathological findings in patients with invasive ductal carcinoma of the breast[J]. Yonago Acta Med, 2016, 59(2): 163-168.
pmid: 27493488
|
| [16] |
Wang D, Zhu K, Tian J, et al. Clinicopathological and ultrasonic features of triple-negative breast cancers: a comparison with hormone receptor-positive/human epidermal growth factor receptor-2-negative breast cancers[J]. Ultrasound Med Biol, 2018, 44(5): 1124-1132. DOI: 10.1016/j.ultrasmedbio.2018.01.013.
pmid: 29482888
|
| [17] |
Ian TWM, Tan EY, Chotai N. Role of mammogram and ultrasound imaging in predicting breast cancer subtypes in screening and symptomatic patients[J]. World J Clin Oncol, 2021, 12(9): 808-822. DOI: 10.5306/wjco.v12.i9.808.
pmid: 34631444
|
| [18] |
刘晓瑜, 林翠君, 黄洁, 等. 不同分子分型乳腺癌的超声、MRI及乳腺X射线摄影特征的诊断价值[J]. 国际放射医学核医学杂志, 2024, 48(2): 74-81. DOI: 10.3760/cma.j.cn121381-202212013-00349.
|
| [19] |
Moreel L, Betrains A, Doumen M, et al. Diagnostic yield of combined cranial and large vessel PET/CT, ultrasound and MRI in giant cell arteritis: a systematic review and meta-analysis[J]. Autoimmun Rev, 2023, 22(7): 103355. DOI: 10.1016/j.autrev.2023.103355.
|
| [20] |
刘春海, 周虎, 刘文静, 等. 超声联合PET/CT及CA153监测乳腺癌术后颈部淋巴结转移的价值[J]. 中国超声医学杂志, 2023, 39(3): 261-265. DOI: 10.3969/j.issn.1002-0101.2023.03.006.
|